HUP9702359A2 - Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens - Google Patents

Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens

Info

Publication number
HUP9702359A2
HUP9702359A2 HU9702359A HUP9702359A HUP9702359A2 HU P9702359 A2 HUP9702359 A2 HU P9702359A2 HU 9702359 A HU9702359 A HU 9702359A HU P9702359 A HUP9702359 A HU P9702359A HU P9702359 A2 HUP9702359 A2 HU P9702359A2
Authority
HU
Hungary
Prior art keywords
monoclonal antibody
production
surface antigen
mammal
antibodies
Prior art date
Application number
HU9702359A
Other languages
English (en)
Inventor
Petrus Gerardus Antonius Steenbakkers
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of HU9702359D0 publication Critical patent/HU9702359D0/hu
Publication of HUP9702359A2 publication Critical patent/HUP9702359A2/hu
Publication of HUP9702359A3 publication Critical patent/HUP9702359A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)

Abstract

A találmány tárgya eljárás felületi antigén elleni mőnőklőnálisantitest előállítására, mely mőnőklőnális antitest elsősőrban őlyanfelületi antigén ellen irányűl, amely egy emlősbe injektált antigénteljes mennyiségéhez viszőnyítva csak jelentéktelen mennyiségben vanjelen, és amely könnyen elveszíti in vivő kőnfőrmációját. A találmányszerinti megőldás példáűl abban az esetben alkalmazható, amikőr egyemlős őltására egy másik emlősfajból származó antigénanyagőt kellalkalmazni. A találmány tárgyát képezi tővábbá a találmány szerintieljárással előállítőtt mőnőklőnális antitest, valamint az ilyenantitesteket tartalmazó gyógyászati készítmény és diagnősztikaireagens. A találmány szerinti eljárás alkalmas kis mennyiségbenjelenlévő sejtfelületi antigén elleni mőnőklőnális antitestelőállítására, még abban az esetben is, mikőr a sejtfelületi antigénkőnfőrmációs szempőntból instabil, és alkalmas receptőrmőlekűlákspecifitást meghatárőzó részei elleni mőnőklőnális antitestekelőállítására. A találmány szerinti megőldás alkalmas mőnőklőnálisantitestek előállítására őlyan esetekben, amikőr nagyőn sők -imműnreakció kiváltására képes - egyéb antigén jelenlétével isszámőlni kell. ŕ
HU9702359A 1996-12-06 1997-12-05 Monoclonal antibody, method of preparing a monoclonal antibody, and pharmaceutical composition and a diagnostic reagent comprising the monoclonal antibody HUP9702359A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203465 1996-12-06
EP97201972 1997-06-27

Publications (3)

Publication Number Publication Date
HU9702359D0 HU9702359D0 (en) 1998-03-02
HUP9702359A2 true HUP9702359A2 (hu) 1998-09-28
HUP9702359A3 HUP9702359A3 (en) 2001-11-28

Family

ID=26143410

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702359A HUP9702359A3 (en) 1996-12-06 1997-12-05 Monoclonal antibody, method of preparing a monoclonal antibody, and pharmaceutical composition and a diagnostic reagent comprising the monoclonal antibody

Country Status (17)

Country Link
US (3) US6020170A (hu)
EP (1) EP0856520B1 (hu)
JP (1) JPH10179160A (hu)
KR (1) KR100543053B1 (hu)
AT (1) ATE322507T1 (hu)
AU (1) AU733165B2 (hu)
BR (1) BR9706236A (hu)
CA (1) CA2221682C (hu)
DE (1) DE69735621T2 (hu)
DK (1) DK0856520T3 (hu)
ES (1) ES2262170T3 (hu)
HU (1) HUP9702359A3 (hu)
IL (1) IL122233A (hu)
NO (1) NO327047B1 (hu)
NZ (1) NZ329314A (hu)
PL (1) PL193821B1 (hu)
PT (1) PT856520E (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934250T2 (de) * 1998-12-22 2007-05-24 Raven Biotechnologies, Inc., South San Francisco Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
SE9902817D0 (sv) 1999-07-30 1999-07-30 A & Science Invest Ab A method for selective electrofusion of at least two fusion partners having cell-like membranes
IL148778A0 (en) * 1999-10-18 2002-09-12 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
EP1319184B1 (en) 2000-08-14 2007-07-25 N.V. Organon Use of antibodies against specific mhc-peptide complexes
EP1418813A4 (en) * 2001-07-24 2009-03-04 Univ Yale METHODS, COMPOSITIONS AND NEEDS RELATING TO CHITINASE AND CHITINASE MOLECULES AND INFLAMMATORY DISEASES
US7018819B2 (en) * 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
WO2004087911A1 (ja) * 2003-03-28 2004-10-14 Toyama New Industry Organization １個の抗原特異的ｂリンパ球を用いた抗原特異的抗体産生ハイブリドーマの作製方法及びモノクローナル抗体の製造方法
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
EP1844073A1 (en) * 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20070071746A1 (en) * 2005-08-31 2007-03-29 Medimmune, Inc. C/CLP antagonists and methods of use thereof
PT3363415T (pt) * 2008-01-09 2019-11-05 Alcon Lensx Inc Fragmentação curva de tecido por laser fotodisruptivo
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0255547A1 (en) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
US5473051A (en) * 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
DE69126281T2 (de) * 1990-11-26 1997-10-16 Akzo Nobel Nv Verfahren zur Herstellung von Antikörpern
US6015884A (en) * 1996-03-28 2000-01-18 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins

Also Published As

Publication number Publication date
AU4690897A (en) 1998-06-11
PL323572A1 (en) 1998-06-08
KR100543053B1 (ko) 2006-06-13
CA2221682C (en) 2011-10-18
US6392020B1 (en) 2002-05-21
AU733165B2 (en) 2001-05-10
BR9706236A (pt) 1999-05-04
ATE322507T1 (de) 2006-04-15
NO327047B1 (no) 2009-04-14
HU9702359D0 (en) 1998-03-02
NO975714D0 (no) 1997-12-05
KR19980063909A (ko) 1998-10-07
IL122233A (en) 2001-04-30
EP0856520A1 (en) 1998-08-05
DK0856520T3 (da) 2006-07-31
HUP9702359A3 (en) 2001-11-28
PT856520E (pt) 2006-08-31
DE69735621T2 (de) 2006-08-24
PL193821B1 (pl) 2007-03-30
IL122233A0 (en) 1998-04-05
NZ329314A (en) 1999-02-25
JPH10179160A (ja) 1998-07-07
MX9709446A (es) 1998-07-31
ES2262170T3 (es) 2006-11-16
DE69735621D1 (de) 2006-05-18
CA2221682A1 (en) 1998-06-06
US6020170A (en) 2000-02-01
US20020143150A1 (en) 2002-10-03
NO975714L (no) 1998-06-08
EP0856520B1 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
HUP9702359A2 (hu) Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens
ES8305419A1 (es) Un peptido
KR890701126A (ko) Nanbv 진단방법 및 백신
ATE425987T1 (de) Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
HUP9902605A2 (hu) A Rhesus-D antigénekre specifikus antigénkötő struktúrák létrehozására képes polipeptidek, az őket kódoló DNS-szekvenciák, továbbá ezek előállítása és alkalmazása
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
HUP0105490A2 (hu) Az IgE C-epszilon-3 vagy C-epszilon-4 doménjéből származtatott epitópok és mimotópok, antagonistáik és terápiás alkalmazásuk
DE69716240D1 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
KR930702387A (ko) Hcv 펩티드-항원 및 c형 간염 바이러스(hcv)의 검사방법
JP3003976B2 (ja) 抗ガングリオシドモノクローナル抗体および悪性腫瘍の特異的能動免疫療法におけるそれらの使用
IL142582A0 (en) Enhanced vaccines
Abeyounis et al. A thermostable antigen characteristic for carcinogen-induced rat intestinal tumors
WO2002012535B1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
JPS6445398A (en) Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
AU2070688A (en) Antigen recognized by mca 16-88
Nimelstein et al. Transformation of a histocompatibility immunogen into a tolerogen
FI924576A (fi) Ctaa 28a32, antigen identiefierad av mca 28a32
KR890008316A (ko) 항응고성 단백질 pp4-x, 및 이의 제조방법 및 용도
ATE140233T1 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
Eggers et al. Induction of anti-idiotypic antibodies to a myeloma protein linked covalently to muramyl dipeptide
Bassiouny ANTIGENICITY OF IN VITRO GLUCOSYLATED PROTEINS AND DIABETIC SECONDARY COMPLICATIONS.
RU97108000A (ru) Вакцина и антитоксин для лечения и предотвращения заболевания, связанного с c.difficile
CS272888B1 (en) Mouse lymphocyte hybridome blvgp 51 ueo-25 e11/2

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: N.V. ORGANON, NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

FD9A Lapse of provisional protection due to non-payment of fees